Cypherpunk Technologies Inc (CYPH)

$0.70 0.00 (-0.44%)
Market Cap 29.72M
Revenue (ttm) 0.00
Net Income (ttm) -67.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,465,900
Avg Vol 2,741,956
Day's Range N/A - N/A
Shares Out 41.44M
Stochastic %K 59%
Beta -0.16
Analysts Strong Buy
Price Target N/A

Company Profile

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an optio...

Industry: Asset Management
Sector: Financial Services
Phone: 617 714 0360
Address:
47 Thorndike Street, Suite B1-1, Cambridge, United States
FinanceWizardAI
FinanceWizardAI Mar. 20 at 5:30 PM
$CYPH
0 · Reply
FinanceWizardAI
FinanceWizardAI Mar. 19 at 6:36 PM
$CYPH Run it back
0 · Reply
StockDreamin
StockDreamin Mar. 19 at 5:45 PM
$CYPH cypherboner
2 · Reply
StockThingzs02
StockThingzs02 Mar. 18 at 8:43 PM
$CYPH thinking whoever sold is about to be really sad the coming days…
0 · Reply
SukhShantiOm
SukhShantiOm Mar. 18 at 8:02 PM
$CYPH added 12k shares today LFG
0 · Reply
StockDreamin
StockDreamin Mar. 18 at 6:51 PM
$CYPH cmon cmon dont slip away
1 · Reply
StockThingzs02
StockThingzs02 Mar. 18 at 1:01 PM
$CYPH everything down 10% today this holding strong.
0 · Reply
RoarinKitty
RoarinKitty Mar. 18 at 11:48 AM
$CYPH 8.03.2026 - 10:51:02 | prnewswire.co.uk Cypherpunk Technologies Inc. Zcash Open Development Lab Massachusetts and http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst Mar. 18 at 1:50 AM
$CYPH https://www.facebook.com/reel/1944146112972515/?referral_source=external_deeplink&original_uri=https%3A%2F%2Fwww.facebook.com%2Fshare%2Fv%2F1FEyT9fTMS%2F%3Fhpir%3D1&http_ref=eyJ0cyI6MTc3Mzc5ODU3MTAwMCwiciI6IiJ9&http_ref=eyJ0cyI6MTc3Mzc5ODU3MTAwMCwiciI6IiJ9
0 · Reply
DubLad76
DubLad76 Mar. 17 at 10:27 PM
$CYPH
0 · Reply
Latest News on CYPH
Cypherpunk Reports Full Year 2025 Financial Results

Mar 16, 2026, 4:50 PM EDT - 5 days ago

Cypherpunk Reports Full Year 2025 Financial Results

Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)

Mar 9, 2026, 9:20 AM EDT - 12 days ago

Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)

Cypherpunk Adds Arjun Khemani as Strategic Advisor

Jan 22, 2026, 7:00 AM EST - 2 months ago

Cypherpunk Adds Arjun Khemani as Strategic Advisor

Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC

Dec 30, 2025, 7:00 AM EST - 2 months ago

Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC

Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor

Dec 19, 2025, 7:00 AM EST - 3 months ago

Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor

Cypherpunk Technologies Inc. (CYPH) Leap Therapeutics, Inc. - Shareholder/Analyst Call Prepared Remarks Transcript

Dec 15, 2025, 12:59 PM EST - 3 months ago

Cypherpunk Technologies Inc. (CYPH) Leap Therapeutics, Inc. - Shareholder/Analyst Call Prepared Remarks Transcript

Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor

Dec 9, 2025, 7:00 AM EST - 3 months ago

Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 8:00 AM EST - 4 months ago

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

Nov 12, 2025, 7:00 AM EST - 4 months ago

Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

Oct 20, 2025, 7:00 AM EDT - 5 months ago

Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Oct 9, 2025, 7:00 AM EDT - 5 months ago

Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Oct 6, 2025, 9:00 AM EDT - 5 months ago

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

Sep 25, 2025, 7:00 AM EDT - 6 months ago

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

Leap Therapeutics Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 7:00 AM EDT - 7 months ago

Leap Therapeutics Reports Second Quarter 2025 Financial Results

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

Jun 23, 2025, 7:00 AM EDT - 9 months ago

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

Leap Therapeutics Reports First Quarter 2025 Financial Results

May 13, 2025, 7:00 AM EDT - 11 months ago

Leap Therapeutics Reports First Quarter 2025 Financial Results

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Apr 25, 2025, 1:00 PM EDT - 11 months ago

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Apr 15, 2025, 7:00 AM EDT - 1 year ago

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Mar 31, 2025, 1:42 PM EDT - 1 year ago

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Mar 26, 2025, 1:29 PM EDT - 1 year ago

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 26, 2025, 7:05 AM EDT - 1 year ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Jan 28, 2025, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Jan 6, 2025, 7:01 AM EST - 1 year ago

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Second Quarter 2024 Financial Results

Leap Therapeutics Reports First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports First Quarter 2024 Financial Results

Leap Therapeutics Announces $40 Million Private Placement

Apr 11, 2024, 8:30 AM EDT - 2 years ago

Leap Therapeutics Announces $40 Million Private Placement

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Jan 16, 2024, 5:05 PM EST - 2 years ago

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Jan 2, 2024, 7:00 AM EST - 2 years ago

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Dec 11, 2023, 4:05 PM EST - 2 years ago

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Nov 21, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Leap Therapeutics to Participate at Upcoming Investor Conferences

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics to Participate at Upcoming Investor Conferences

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Jul 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split

Jun 20, 2023, 12:30 PM EDT - 2 years ago

Leap Therapeutics Announces Reverse Stock Split

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

May 25, 2023, 5:10 PM EDT - 3 years ago

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Leap Therapeutics Reports First Quarter 2023 Financial Results

May 15, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Reports First Quarter 2023 Financial Results

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Apr 12, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 24, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

Mar 16, 2023, 4:05 PM EDT - 3 years ago

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

FinanceWizardAI
FinanceWizardAI Mar. 20 at 5:30 PM
$CYPH
0 · Reply
FinanceWizardAI
FinanceWizardAI Mar. 19 at 6:36 PM
$CYPH Run it back
0 · Reply
StockDreamin
StockDreamin Mar. 19 at 5:45 PM
$CYPH cypherboner
2 · Reply
StockThingzs02
StockThingzs02 Mar. 18 at 8:43 PM
$CYPH thinking whoever sold is about to be really sad the coming days…
0 · Reply
SukhShantiOm
SukhShantiOm Mar. 18 at 8:02 PM
$CYPH added 12k shares today LFG
0 · Reply
StockDreamin
StockDreamin Mar. 18 at 6:51 PM
$CYPH cmon cmon dont slip away
1 · Reply
StockThingzs02
StockThingzs02 Mar. 18 at 1:01 PM
$CYPH everything down 10% today this holding strong.
0 · Reply
RoarinKitty
RoarinKitty Mar. 18 at 11:48 AM
$CYPH 8.03.2026 - 10:51:02 | prnewswire.co.uk Cypherpunk Technologies Inc. Zcash Open Development Lab Massachusetts and http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst Mar. 18 at 1:50 AM
$CYPH https://www.facebook.com/reel/1944146112972515/?referral_source=external_deeplink&original_uri=https%3A%2F%2Fwww.facebook.com%2Fshare%2Fv%2F1FEyT9fTMS%2F%3Fhpir%3D1&http_ref=eyJ0cyI6MTc3Mzc5ODU3MTAwMCwiciI6IiJ9&http_ref=eyJ0cyI6MTc3Mzc5ODU3MTAwMCwiciI6IiJ9
0 · Reply
DubLad76
DubLad76 Mar. 17 at 10:27 PM
$CYPH
0 · Reply
FoxyDreams
FoxyDreams Mar. 17 at 9:37 PM
~@SqueezeSharkie is on another level, outperforming 90% of traders on this platform. .If you’re not following yet, you’re leaving value on the table. Takes 2 seconds and it’s free. 💎 $JZ $ISPC $CYPH $RFIL >> on watch
0 · Reply
atechniqueisause
atechniqueisause Mar. 17 at 6:46 PM
$CYPH Hyperpunk?
0 · Reply
StockThingzs02
StockThingzs02 Mar. 17 at 6:20 PM
$CYPH sound the alarm bears are panicking
0 · Reply
Hegotgame88
Hegotgame88 Mar. 17 at 6:09 PM
$CYPH
0 · Reply
StockThingzs02
StockThingzs02 Mar. 17 at 5:32 PM
$CYPH dip ?
0 · Reply
no1patfan
no1patfan Mar. 17 at 4:44 PM
$CYPH Something
0 · Reply
atechniqueisause
atechniqueisause Mar. 17 at 4:39 PM
$CYPH
0 · Reply
automaticstatic
automaticstatic Mar. 17 at 3:19 PM
$CYPH Is this what's moving this Net Income was $4.8 million for the year ended December 31, 2025, compared to a Net Loss of $67.8 million for the year ended December 31, 2024.
0 · Reply
automaticstatic
automaticstatic Mar. 17 at 3:17 PM
$CYPH is this squeezing ? Hopefully to a big number
0 · Reply
BiodegradableBurger
BiodegradableBurger Mar. 17 at 3:01 PM
$CYPH Stay above $1 for >10 days muthafcka
0 · Reply
michaelburryburner
michaelburryburner Mar. 17 at 2:44 PM
$CYPH squeezing $ZEC.X
0 · Reply
SexyStockSlayer
SexyStockSlayer Mar. 17 at 2:40 PM
$CYPH added that dip, thanks, .69 ave now $ZEC.X
0 · Reply